May 2012
In This Issue:
May is ALS Awareness Month
Distance swimming for ALS
MDA 2012 Clinical Conference provided updates from top experts
Dr. Howell receives lifetime achievement award
Christie comes back for more
Heat shock proteins provide new approach to DMD treatment
SMA disease course may be affected by ZPR1
Repligen launches Italian trial of experimental drug for FA
Mitochondrial dysfunction may play a role in some forms of ALS
Feedback
Privacy Policy
Previous Issues:
March 2012
December 2011
November 2011
August 2011
Pass it along!
Feel free to send your friends a link to this MDA
e-update.
|
Welcome to the MDA e-update, the Muscular Dystrophy Association's online newsletter that reports MDA's research breakthroughs and other information to friends whose support helps make our programs possible.
MDA NEWS
May is ALS Awareness Month
What do these three people have in common: Former Boy Scout leader Ben Thomas; Brian Carless, a local radio and television regular who loves baseball and photography; and Robin Mower, a Special Olympics powerlifting coach and fitness coach?
Each of them has ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease) and each will be profiled in MDA's online series Anyone's Life Story® during national ALS Awareness Month this May.
Beginning May 1, be sure to visit mda.org each day to meet 31 inspiring individuals — one per day — who are living with ALS. In addition to the profiles, a section called "ALS: It's My Story, Too" provides a forum where family and friends can describe how ALS impacts their lives.
Other MDA ALS events scheduled across the country during May include educational programs, support group presentations and fundraisers. This is the 21st year that MDA has conducted special activities in conjunction with ALS Awareness Month, in an effort to build awareness of this rare and devastating disease, and support for finding a cure.

Distance swimming for ALS
Spaniard Jaime Caballero joined an elite list of long-distance swimmers in April after swimming from Catalina Island to Palos Verdes, Calif. It helped him reach two goals: He became a rare member of the Triple Crown of Open Water Swimming, and he helped raise money for ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) research.
 |
| Jaime Caballero
|
Caballero, a 37-year-old native of San Sebastian, Spain, finished in 9 hours and 31 minutes, swimming in 53-degree water.
He raised $100,000, a portion of which will go to MDA's Augie's Quest ALS research initiative.
"My reason for doing this is to raise money to find a cure for ALS," he said. "Many of us, including me, have lost family members to this disease." Caballero's uncle passed away in 2009 from ALS. Since 2011, Caballero has raised nearly $150,000 for ALS research through sponsors, contributions and swimming events.
MDA 2012 Clinical Conference provided updates from top experts
The latest advances in diagnosis, medical management and emerging therapies for neuromuscular diseases were presented to more than 500 attendees at the 2012 MDA Clinical Conference in March.
The conference — the second in MDA's new annual national conference series — provided MDA clinic directors and clinic team members with updates from top experts for many of the diseases in MDA’s program, including the muscular dystrophies, inherited neuropathies, motor neuron diseases and autoimmune neuromuscular diseases.
About half the conference participants were physicians from such specialties as neurology, physical medicine and rehabilitation, cardiology and pulmonology. Other participants included nurses, nurse practitioners, therapists, genetic counselors, social workers and MDA health care service coordinators.
Four daily blogs, including two from individuals with neuromuscular diseases, provided an overview and "human perspective" on the conference proceedings.
Dr. Howell receives lifetime achievement award
R. Rodney Howell, M.D., renowned pediatrician and geneticist, and current chairman of the Board of Directors for the Muscular Dystrophy Association, received a special award in April: the 2012 American College of Medical Genetics (ACMG) Foundation Lifetime Achievement Award.
 |
| R. Rodney Howell, M.D.
|
Howell was honored for his work in the field of pediatrics and genetic research, and for his leadership in the development and advancement of newborn screening.
A lifelong advocate for children, Howell has been a strong voice for newborn screening since the 1960s, serving on numerous high-level governmental committees over the years. His leadership is part of the reason why, today, nearly 95 percent of the 4.1 million children born in the U.S. each year are screened for some 30 genetic disorders.
"We're proud of Dr. Howell and this well-deserved honor," said MDA Medical Director and Interim President Valerie Cwik, M.D., noting that his guidance and expertise are "invaluable as we explore the potential for early detection and early treatment of neuromuscular diseases."
Howell has been a member of the MDA board since 1994, and also has served as chair of the MDA Scientific Advisory Committee. "Dr. Howell is outstanding at what he does," said Cwik. "The MDA family is truly fortunate to have him."
Christie comes back for more
In recognition of his stellar ability to excite teenagers and young adults about MDA's lifesaving mission, Luke Christie has been named to a fourth term as the Muscular Dystrophy Association's National Youth Chairman.
 |
| Luke Christie
|
As youth chairman, Christie speaks to such youth-oriented MDA national sponsors as DECA (an association of marketing students), Kappa Alpha Order and The National Beta Club.
"I'm always grateful for the opportunity to share MDA's story with teens and young adults," said Christie, 18, who is a freshman communications major at Furman University in Greenville, S.C. "Through my experience in living with a muscle disease, I feel that I can have an impact on my generation; I'm always approached by students wanting to know how to help."
Christie has spinal muscular atrophy, a progressive neuromuscular disease that causes muscle weakness and atrophy. The former MDA National Goodwill Ambassador (2006 and 2007) relies on a power wheelchair for mobility.


RESEARCH NEWS
Heat shock proteins provide new approach to DMD treatment
New research suggests that a potential strategy for treating Duchenne muscular dystrophy (DMD) may be to increase levels of heat shock proteins, naturally occurring proteins that assist in the folding and unfolding of other proteins. Working with mice with a DMD-like disease, an Australian research team (supported in part by MDA) found that elevating levels of heat shock protein 72 (HSP72) resulted in improved structure, strength and function in severely affected muscles. HSP72 worked by interacting with a protein that regulates levels of potentially damaging calcium ions in DMD-affected muscle fibers. The researchers suggest that strategies to increase HSP72 potentially could be used alone or in combination with other DMD therapies under development, such as those that increase dystrophin or utrophin levels.
SMA disease course may be affected by ZPR1
Adequate levels of zinc finger protein 1 (ZPR1) appear to be a "protective" modifier of spinal muscular atrophy (SMA), an MDA-supported team of scientists has reported. Modifiers influence disease onset and severity by changing various biological pathways. Researchers found that in mice with an SMA-like disease, adequate levels of ZPR1 correlated with milder SMA symptoms, while reduced ZPR1 activity was associated with more severe symptoms. The identification of ZPR1 as a modifier reveals a potential target for therapy development and also sheds light on the mechanisms that drive SMA. In addition, testing to determine ZPR1 protein levels could help inform physicians and families about the likely disease course in affected individuals.
Repligen launches Italian trial of experimental drug for FA
The first human trial of a therapy specifically developed to treat Friedreich's ataxia (FA) has been launched in Turin, Italy, by Repligen Corp. MDA awarded Repligen two large grants that helped advance the experimental therapy, RG2833, to the stage where it was ready to be tested in humans. About 20 adults with FA will be enrolled in the double-blinded phase 1 trial, to assess the drug's safety and tolerability. RG2833 belongs to a class of drugs called histone deacetylase (HDAC) inhibitors and is thought to work by activating the frataxin gene (which is abnormally "turned off" in FA), allowing cellular machinery to read its genetic instructions and produce the frataxin protein. Frataxin protein deficiency is the underlying cause of FA.
Mitochondrial dysfunction may play a role in some forms of ALS
Mitochondrial dysfunction appears even more likely to be a contributing factor in some forms of ALS, based on reports from an MDA-supported research team. In experiments with adult nematodes (a type of roundworm), the team found that disrupting signaling by major sperm protein (MSP) resulted in the development of "massive" abnormalities in the mitochondria, the vital energy producers found within cells. In worms in which the researchers stopped MSP from signaling muscle cell receptors, the mitochondria did not properly localize in the areas of the muscle where energy is required most, and they produced 30 to 40 percent less energy than normal. MSP is a subunit of the human VAPB protein, which was found in 2007 to be responsible for a form of inherited ALS called ALS8.
Feedback
Feedback about this newsletter is welcome. General correspondence may be addressed to mda@helpmda.org.
Privacy Policy
Information in the MDA website is for educational purposes only, and is not intended to replace, and should not be interpreted or relied upon as, professional advice. By accessing the MDA website, you agree to the terms and conditions contained in its disclaimers. Please read MDA's Terms of Use and Privacy Policy.
|